Shares of Ventrus Biosciences (NASDAQ:VTUS) pop, subsequent to the announcement that Phase III trials of its Diltiazem treatment for the relief of pain associated with anal fissures showed significant improvements over placebos.
Hospira (NYSE:HSP) slides following word of a voluntary recall during the weekend of one lot of its Hydromorphone Injection, because of two reported complaints of a single Carpuject containing more than the 1 mL labeled fill volume. Overdoses of such medications can be lethal.
Don’t Miss: Zumiez First Quarter Earnings Sneak Peek.
Novartis’ (NYSE:NVS) multiple sclerosis drug Gilenya is rumored to be linked to patient deaths, but the FDA says that it can’t formally conclude such a validity. However, the cardiovascular effects of the treatment following the first dose, remain a concern to the agency.
Healthcare firms such as Biogen (NASDAQ:BIIB), CareFusion (NYSE:CFN), Celgene (NASDAQ:CELG), Lab Corp. (NYSE:LH), and Life Tech (NASDAQ:LIFE) are among those who might give in to peer pressure and begin paying dividends to investors who crave “immediate, stable income amid today’s low interest rate environment”, according to Moody’s.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.